kabutan

Solasia Pharma K.K.(4597) Summary

4597
TSE Growth
Solasia Pharma K.K.
32
JPY
+1
(+3.23%)
Dec 12, 3:30 pm JST
0.20
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
31.2
Dec 12, 11:25 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.63
Yield
ー%
Margin Trading Ratio
2.75
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
31 JPY 0.19 USD
Previous Close Dec 11
31 JPY 0.19 USD
High Dec 12, 9:02 am
32 JPY 0.20 USD
Low Dec 12, 1:17 pm
30 JPY 0.19 USD
Volume
63,406,800
Trading Value
1.97B JPY 0.01B USD
VWAP
31.05 JPY 0.2 USD
Minimum Trading Value
3,200 JPY 20 USD
Market Cap
8.33B JPY 0.05B USD
Number of Trades
267
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Mid
1-Year Average
394
1-Year High Jun 27, 2025
2,772
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 1,838,200 24,711,700 13.44
Nov 28, 2025 2,243,300 24,394,500 10.87
Nov 21, 2025 4,412,600 26,143,800 5.92
Nov 14, 2025 4,398,800 25,774,300 5.86
Nov 7, 2025 3,126,900 26,472,600 8.47
Company Profile
Solasia Pharma K.K. is a biopharmaceutical venture company focused on cancer and malignant tumor drug discovery. The company engages in the development of pharmaceuticals and medical devices, with a primary focus on clinical development.
Sector
Pharmaceuticals
Solasia Pharma K.K. operates as a biopharmaceutical venture company specializing in the oncology field, developing both pharmaceuticals and medical devices. The company primarily concentrates on clinical development, introducing promising new drug candidates and conducting trials in Japan and other Asian countries. With multiple development pipelines, Solasia focuses on treatments for malignant tumors and supportive care medications. Their product portfolio includes darinaparsin for peripheral T-cell lymphoma, a transdermal granisetron preparation for preventing chemotherapy-induced nausea and vomiting, and a medical device aimed at alleviating pain from oral mucositis. The company's business model encompasses the entire process from clinical development to regulatory submission and out-licensing of marketing rights. Solasia aims to generate revenue through out-licensing to pharmaceutical companies, which includes sales revenue, milestone payments, and royalty income.